Posted innews
Recognizing the Signs of Perimenopause: A Guide for Women
Explore the six common signs of perimenopause and learn practical strategies to manage this transitional phase effectively.
Posted inGeneral Surgery news Specialties
When Do Thyroid Nodules Require Surgery? Clear Answers Here
Thyroid nodules larger than 4 cm often require surgery due to potential compression of surrounding tissues, but smaller nodules with signs of malignancy or symptoms may also need surgical intervention. This article explains the criteria in detail.
Understanding the Differences Between Breast Hyperplasia and Breast Nodules
This article provides an in-depth comparison of breast hyperplasia and breast nodules, highlighting their definitions, symptoms, causes, diagnostic methods, and treatment options.
Understanding Ovulation Bleeding: Normal or a Sign of Disease?
Explore the causes, symptoms, and implications of ovulation bleeding, distinguishing between normal physiological occurrences and potential health concerns.
Posted innews Orthopedics Specialties
Three Diseases to Watch for When Experiencing Shoulder Pain: Don’t Mistake These Pain Locations for Frozen Shoulder
Shoulder pain is often attributed to frozen shoulder, but cervical spondylosis, cholecystitis, and heart disease can also cause shoulder pain. Correct diagnosis is crucial to avoid treatment delays and complications.
Posted innews Orthopedics Specialties
Understanding Brown Discharge After Intimacy: Causes and When to Seek Help
Explore the causes of brown vaginal discharge after sexual activity, distinguishing between normal physiological responses and potential health concerns.
Posted innews OB/GYN & Women's Health Specialties
White Clumpy Vaginal Discharge? It Could Be These 3 Common Gynecological Issues!
White clumpy vaginal discharge can signal common gynecological conditions like yeast infections, bacterial vaginosis, or normal physiological changes. Understanding symptoms and seeking appropriate care is crucial for women's health.
Daratumumab Plus VTd Induction and Maintenance: Transforming Outcomes in Newly Diagnosed Multiple Myeloma—Long-Term MRD and PFS Insights from CASSIOPEIA
Long-term CASSIOPEIA results confirm daratumumab plus VTd induction/consolidation and daratumumab maintenance deliver deepest MRD negativity and superior PFS in transplant-eligible, newly diagnosed myeloma.
Venetoclax in Relapsed/Refractory Multiple Myeloma: Balancing Disease Control and Survival—Final Results from the BELLINI Phase 3 Trial
Final BELLINI trial results show improved progression-free survival with venetoclax in relapsed/refractory multiple myeloma, but increased early mortality negates overall survival benefit, prompting caution for general use.
Olverembatinib Plus Venetoclax and Reduced-Intensity Chemotherapy: A Promising New Frontier for Adult Philadelphia Chromosome-Positive Acute Lymphoblastic Leukemia
A phase 2 trial shows that olverembatinib combined with venetoclax and reduced-intensity chemotherapy achieves high molecular response and survival rates in newly diagnosed Ph+ ALL patients, offering a less intensive alternative.
Surgery or Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF Trials
The SURF trials found no significant difference in survival or recurrence-free outcomes between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting RFA as a less invasive, equally effective option.
First-Line Camizestrant for ESR1-Mutated Advanced Breast Cancer: Redefining Endocrine Therapy Resistance
Next-generation SERD camizestrant significantly prolongs progression-free survival over aromatase inhibitors or fulvestrant in ESR1-mutated, ER-positive, HER2-negative advanced breast cancer, with favorable safety and quality-of-life profiles.
Vepdegestrant: A Next-Generation Oral PROTAC ER Degrader for Advanced ER+/HER2– Breast Cancer—VERITAC-2 Results and Clinical Implications
Vepdegestrant, an oral PROTAC estrogen receptor degrader, significantly prolongs progression-free survival compared to fulvestrant in ESR1-mutant advanced breast cancer, but not in the overall ER+/HER2– population.
Posted inClinical Updates news Oncology Radiology Specialties
Reduced Elective Radiotherapy Dose in Head and Neck Cancer: New Evidence from the UPGRADE-RT Trial
The UPGRADE-RT multicenter trial confirms that lowering elective neck irradiation dose in definitive radiotherapy for head and neck cancer maintains disease control and improves quality of life, reducing toxicity without increasing recurrence risk.
Posted inClinical Updates news Oncology Specialties
Timing Matters: Sequential Pembrolizumab Plus Chemoradiation Outperforms Concurrent Approach in Locally Advanced Head and Neck Cancer
A Phase II trial finds sequential pembrolizumab after chemoradiation achieves superior locoregional control compared to concurrent administration in locally advanced head and neck squamous cell carcinoma.
Long-Term Outcomes of Transoral Surgery with Risk-Adapted Adjuvant Therapy in HPV-Positive Oropharyngeal Cancer: Results from the E3311 Trial
The E3311 phase II trial shows excellent long-term survival with deintensified postoperative management after transoral surgery in HPV-associated oropharyngeal cancer, with most patients spared from high-dose radiation and chemotherapy.
Triplet Therapy Advances: Azacitidine, Venetoclax, and Revumenib in Newly Diagnosed NPM1-Mutated or KMT2A-Rearranged AML
A phase I trial demonstrates high remission rates and manageable safety for azacitidine, venetoclax, and revumenib in older adults with newly diagnosed NPM1-mutated or KMT2A-rearranged AML, offering new hope for these high-risk patients.
Glofitamab Combined With Pola-R-CHP or R-CHOP as First Therapy in Younger Patients With High-Risk Large B-Cell Lymphoma: Results From the COALITION Study
This phase II trial shows that combining glofitamab with R-CHOP or Pola-R-CHP is safe and effective as first-line treatment in younger patients with high-risk large B-cell lymphoma, achieving high durable response rates and manageable side effects.
Posted inClinical Updates news Oncology Specialties
Personalizing Oxaliplatin Dosing: Reducing Neurotoxicity in Stage III Colon Cancer—Insights from the LEANOX Trial
LBM-based oxaliplatin dosing significantly reduces peripheral neurotoxicity without compromising survival outcomes in adjuvant treatment for stage III colon cancer.
Surgery versus Radiofrequency Ablation for Small Hepatocellular Carcinoma: Insights from the SURF-RCT and SURF-Cohort Trials
The SURF trials found no significant difference in survival or recurrence between surgery and radiofrequency ablation for small hepatocellular carcinoma, supporting both as valid first-line options.